Table 3.
Within and between groups analyses in other clinical scales.
| n | Minocycline | n | Placebo | Between-groups statistics | |
|---|---|---|---|---|---|
| BDI-II mean (SD) | |||||
| Baseline | 18 | 24.27 (9.75) | 21 | 26.71 (9.20) | |
| Week 4 | 18 | 17.33 (20.75) | 21 | 20.38 (17.11) | |
| Mean change | 18 | 6.94 (8.46)* | 21 | 6.33 (7.17)* | t = 0.24, p = 0.81 |
| CGI mean (SD) | |||||
| Baseline | 17 | 4.41 (0.50) | 20 | 4.30 (0.92) | |
| Week 4 | 18 | 3.44 (1.19) | 21 | 3.81 (0.87) | |
| Mean change | 17 | 0.94 (1.14)* | 20 | 0.45 (0.94)** | t = 1.43, p = 0.16 |
| PSS mean (SD) | |||||
| Baseline | 18 | 26.05 (4.96) | 21 | 28.61 (4.90) | |
| Week 4 | 18 | 21.50 (8.29) | 21 | 24.42 (6.15) | |
| Mean change | 18 | 4.55 (6.08)* | 21 | −4.19 (5.23)* | t = 0.20, p = 0.84 |
| SHAPS mean (SD) | |||||
| Baseline | 17 | 7.18 (3.69) | 18 | 5.60 (3.50) | |
| Week 4 | 18 | 4.61 (4.92) | 19 | 4.20 (4.21) | |
| Mean change | 17 | 3.00 (4.00)** | 18 | 2.00 (2.66)* | t = 0.88, p = 0.38 |
| STAI-S mean (SD) | |||||
| Baseline | 17 | 51.18 (11.68) | 21 | 54.09 (8.56) | |
| Week 4 | 17 | 47.33 (13.77) | 21 | 48.67 (11.19) | |
| Mean change | 17 | 4.05 (11.40) | 21 | 5.43 (8.62)* | t = −0.42, p = 0.67 |
| STAI-T mean (SD) | |||||
| Baseline | 16 | 57.75 (8.15) | 19 | 59.48 (6.37) | |
| Week 4 | 16 | 49.69 (13.14) | 21 | 54.31 (8.97) | |
| Mean change | 14 | 5.57 (9.47)** | 19 | 5.58 (10.18)** | t = 0.002, p = 0.99 |
BDI-II Beck Depression Inventory II, CGI Clinical Global Impression scale, PSS Perceived stress scale, SHAPS Snaith–Hamilton Pleasure Scale, STAI-S Spielberger State-Trait Anxiety Rating Scale-State, STAI-T Spielberger State-Trait Anxiety Rating Scale-Trait.
*Within-group paired t-test, p < 0.01; **within-group paired t-test, p < 0.05.
Bold means that the results are statistically significant.